Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – What’s Next?

Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) shares gapped down prior to trading on Monday . The stock had previously closed at $44.75, but opened at $42.11. Zealand Pharma A/S shares last traded at $42.11, with a volume of 110 shares trading hands.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on ZLDPF shares. Wolfe Research cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 11th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Zealand Pharma A/S in a research note on Thursday, June 4th. Cantor Fitzgerald restated a “neutral” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. William Blair reiterated a “market perform” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. Finally, BNP Paribas Exane cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 6th. Three analysts have rated the stock with a Strong Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat, Zealand Pharma A/S has a consensus rating of “Moderate Buy”.

Get Zealand Pharma A/S alerts:

Check Out Our Latest Stock Analysis on ZLDPF

Zealand Pharma A/S Price Performance

The company has a debt-to-equity ratio of 0.02, a quick ratio of 37.17 and a current ratio of 37.17. The company has a market cap of $3.01 billion, a price-to-earnings ratio of 3.12 and a beta of 0.86. The company’s 50 day moving average price is $47.67 and its 200-day moving average price is $55.51.

Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.37) by $0.50. The business had revenue of $5.33 million during the quarter, compared to analyst estimates of $2.81 million. Zealand Pharma A/S had a return on equity of 41.80% and a net margin of 68.82%. On average, equities research analysts forecast that Zealand Pharma A/S will post 2.37 earnings per share for the current fiscal year.

Zealand Pharma A/S Company Profile

(Get Free Report)

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.

Featured Stories

• Five stocks we like better than Zealand Pharma A/S
• onsemi: What the Market Gets Wrong, You Can Get Right
• Is McCormick a Steal Ahead of Game-Changing Unilever Deal?
• Qualcomm’s Investor Day Just Changed the Growth Story Forever
• JPMorgan Stands by Sky-High Broadcom Target as Shares Slide

Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.